SCHEMBL21024574

SCHEMBL21024574

N#Cc1cnc(-c2nnc(N[C@H]3C=C(c4ccccc4)c4ccccc4NC3=O)o2)c(N2CCOCC2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 6/20 0.35
▸ MST1 P26927 1/20 0.34
▸ STK4 Q13043 1/20 0.34
▸ STK3 Q13188 1/20 0.34
▸ STK26 Q9P289 1/20 0.34
▸ FPR1 P21462 1/20 0.33
▸ FPR2 P25090 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ PRKDC P78527 2/20 0.32
▸ CBLB Q13191 4/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ CASP7 P55210 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ CLK4 Q9HAZ1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21024568 0.94 FPR1 (0.32) FPR1FPR2ALDH1A1KMT2APRKDC
SCHEMBL21024549 0.90 FPR1 (0.34) LRRK2FPR1FPR2ALDH1A1KMT2A
SCHEMBL21024564 0.88 DDB1 (0.34) FPR1FPR2ALDH1A1KMT2APRKDC
SCHEMBL21024548 0.88 FPR1 (0.34) FPR1FPR2ALDH1A1KMT2APRKDC
SCHEMBL21024562 0.87 DDB1 (0.33) FPR1FPR2ALDH1A1KMT2APRKDC
SCHEMBL20098252 0.85 CCKBR (0.44) LRRK2CBLBCCKBR
SCHEMBL20098124 0.85 CCKBR (0.44) LRRK2CBLBCCKBR
SCHEMBL21024547 0.82 KDM4E (0.38) LRRK2STK4STK3FPR1FPR2
SCHEMBL20098480 0.79 CBLB (0.43) CBLBCCKBR
SCHEMBL24611920 0.79 LRRK2 (0.36) LRRK2MST1STK4STK3STK26

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647711-B2 Azepin-2-one derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-05-12 — — US disclosed
US-20190152968-A1 AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152968-A1 AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS AZI2, FURIN, ACE2 LRRK2 4406/4885MST1 2026/4885STK4 1456/4885
US-10647711-B2 Azepin-2-one derivatives as RSV inhibitors AZI2, FURIN, ACE2 LRRK2 4406/4885MST1 2026/4885STK4 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback